#SFHS2610600AFrance adds WINREVAIR presentations to the approved medicines list for public institutions
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds eight WINREVAIR 45 mg and 60 mg presentations, containing sotatercept, to France’s list of medicines approved for use by public institutions and public services. Health facilities and public-sector purchasers can use the listed presentations under the approved framework. Reimbursement by health insurance is limited to the therapeutic indication covered by the marketing authorization in force on the publication date.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds eight WINREVAIR 45 mg and 60 mg presentations to the approved medicines list for public institutions
- Covers different vial and injection-kit presentations supplied by MSD France
- Limits health insurance reimbursement to the indication approved in the marketing authorization at publication
Obligations
What this law requires
Public health institutions and public services may procure and use only the eight listed WINREVAIR 45 mg and 60 mg sotatercept presentations under the approved collectivities/public services medicines list.
Health insurance reimbursement for the listed WINREVAIR presentations must be limited to the therapeutic indication appearing in the marketing authorization in force on the publication date of this order.